Mutation detection in Croatian patients with familial hypercholesterolemia
Ivan Pećin1, Ros Whittall, Marta Futema
1Department of Internal Medicine, University Hospital Center Zagreb, Croatia.
Insights
Genetic analysis identified causative mutations in 88% of familial hypercholesterolemia (FH) patients, revealing novel variants and highlighting genetic diversity in Croatia for improved diagnosis and prevention of heart disease.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Molecular Biology
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder leading to premature heart disease.
- Mutations in LDLR, APOB, or PCSK9 genes cause FH.
- Accurate genetic diagnosis is crucial for patient treatment and cascade screening of relatives.
Purpose of the Study:
- To identify causative genetic mutations in clinically diagnosed Familial hypercholesterolemia patients.
- To evaluate the utility of High-Resolution Melting (HRM) analysis for FH mutation screening.
- To investigate the spectrum of genetic variants in FH patients from Croatia.
Main Methods:
- DNA analysis of eight unrelated FH patients.
- High-Resolution Melting (HRM) for LDLR, APOB, and PCSK9 genes.
- Sanger sequencing, predictive algorithms, and MLPA for variant analysis.
Main Results:
- Identified three novel pathogenic LDLR variants (p.(S470C), p.(C698R), c.2312-2A>C).
- Confirmed previously reported mutations in LDLR and identified a pathogenic APOB variant (p.(R3527Q)).
- Causative mutations were found in 88% of patients; no PCSK9 variants or large LDLR deletions/insertions were detected.
Conclusions:
- High-Resolution Melting (HRM) is an effective screening method for FH mutations.
- Significant allelic heterogeneity exists in Croatian FH patients.
- Genetic identification enables targeted treatment and preventative strategies for FH.
Abstract:
Familial hypercholesterolemia (FH) is caused by mutations in the genes for LDLR, APOB or PCSK9, and identification of the causative mutation provides definitive diagnosis so that the patient can be treated, their relatives tested and, therefore, premature heart disease prevented. DNA of eight unrelated individuals with clinically diagnosed FH were analyzed using a High-Resolution Melting method (HRM) for the LDLR gene (coding region, promoter and intron/exon boundaries), the APOB gene (part exon 26) and the PCSK9 gene (exon7). Variations found were sequenced and the effect on function of confirmed variants examined using predictive algorithms. Gross deletions and insertions were analysed using MLPA. Three novel LDLR variants were found, p.(S470C), p.(C698R) and c.2312-2A>C. All were predicted to be pathogenic using predictive algorithms. Three previously reported disease-causing mutations were identified (p.(G20R), p.(N272T) and p.(S286R); the latter was also carried by a hypercholesterolaemic relative. One patient carried the pathogenic APOB variant p.(R3527Q). No large LDLR deletions nor insertions were found, neither were any PCSK9 variants identified. HRM is a sensitive method for screening for mutations. While the causative mutation has been identified in 88% of these clinically defined FH patients, there appears to be a high degree of allelic heterogeneity in Croatian patients.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Point and Frameshift Mutations
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
